Critical drug interaction between ritonavir-boosted atazanavir regimen and non-nucleoside reverse transcriptase inhibitors.

作者信息

Poirier Jean-Marie, Guiard-Schmid Jean-Baptiste, Meynard Jean-Luc, Bonnard Philippe, Zouai Ouahiba, Lukiana Tuna, Jaillon Patrice, Girard Pierre-Marie, Pialoux Gilles

出版信息

AIDS. 2006 Apr 24;20(7):1087-9. doi: 10.1097/01.aids.0000222092.97776.cd.

DOI:10.1097/01.aids.0000222092.97776.cd

PMID:16603872

Abstract

摘要

相似文献

Critical drug interaction between ritonavir-boosted atazanavir regimen and non-nucleoside reverse transcriptase inhibitors.

AIDS. 2006 Apr 24;20(7):1087-9. doi: 10.1097/01.aids.0000222092.97776.cd.

Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes.

Prescrire Int. 2009 Jun;18(101):104.

Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study.

HIV Med. 2010 Jan;11(1):40-5. doi: 10.1111/j.1468-1293.2009.00740.x. Epub 2009 Aug 3.

Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.

Pharmacotherapy. 2008 Mar;28(3):323-30. doi: 10.1592/phco.28.3.323.

Anti-HIV agents. Atazanavir as a booster for protease inhibitors.

TreatmentUpdate. 2003 Jun-Jul;15(4):1-2.

Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients.

Antivir Ther. 2010;15(7):1035-8. doi: 10.3851/IMP1647.

Anti-HIV agents. Atazanavir and saquinavir.

TreatmentUpdate. 2004 Apr-May;16(3):9-10.

Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.

J Antimicrob Chemother. 2009 Jul;64(1):118-25. doi: 10.1093/jac/dkp146. Epub 2009 May 6.

Drug interactions. Kaletra and atazanavir.

TreatmentUpdate. 2006 Jun-Jul;18(3):7-8.

Virological failure and subsequent resistance profiles in individuals exposed to atazanavir.

AIDS. 2007 Aug 20;21(13):1826-8. doi: 10.1097/QAD.0b013e3282742000.

引用本文的文献

The Expanding Class of Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV-1 Infection.

P T. 2011 Jun;36(6):346-64.

Efavirenz in the therapy of HIV infection.

Expert Opin Drug Metab Toxicol. 2010 Jan;6(1):95-103. doi: 10.1517/17425250903483207.

Factors influencing lopinavir and atazanavir plasma concentration.

J Antimicrob Chemother. 2010 Jan;65(1):129-37. doi: 10.1093/jac/dkp408.

Efavirenz: a decade of clinical experience in the treatment of HIV.

J Antimicrob Chemother. 2009 Nov;64(5):910-28. doi: 10.1093/jac/dkp334. Epub 2009 Sep 18.

Atazanavir: a review of its use in the management of HIV-1 infection.

Drugs. 2009 May 29;69(8):1107-40. doi: 10.2165/00003495-200969080-00009.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验